Starlight Therapeutics

Executive Summary

Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma, is developing STAR-001, an AI-driven small molecule treatment for glioblastoma, brain metastases, and pediatric CNS cancers. The company leverages Lantern Pharma's AI platform to accelerate drug development and improve patient outcomes. Currently in Phase 1 clinical trials, Starlight aims to address significant unmet needs in CNS oncology, where treatment options remain limited. The AI-driven approach potentially enables more efficient patient stratification and biomarker identification, which could enhance the probability of success. As a private company, Starlight benefits from Lantern Pharma's resources and expertise, while maintaining focus on its proprietary pipeline. The early-stage nature and narrow focus on CNS cancers present both opportunities and risks, with key upcoming milestones expected to shape the company's trajectory.

Upcoming Catalysts (preview)

• Q3 2026Initial Phase 1 safety and efficacy data readout for STAR-001 in glioblastoma30% success
• Q4 2026Regulatory update for expansion into pediatric CNS cancer indications40% success
• TBDPotential partnership or collaboration with a larger biopharma for CNS pipeline25% success